Login to Your Account



Includes Four Disease Areas

Alnylam Captures Potential $1B Roche Licensing Deal

By Randall Osborne


Tuesday, July 10, 2007
Deep-pocketed big pharma plighted its figurative troth with the last high-profile player in RNA interference, Alnylam Pharmaceuticals Inc., in a non-exclusive licensing deal that could mean as much as $1 billion from Roche Holding AG - with $331 million up front that includes an equity investment of $42.5 million, for less than 5 percent of Alnylam's outstanding shares. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription